The Commission proposes to revise the EU’s pharmaceutical legislation – the largest reform in over 20 years – to make it more agile, flexible, and adapted to the needs of citizens and businesses across the EU. The revision will make medicines more available, accessible and affordable. It will support innovation and boost the competitiveness and attractiveness of the EU pharmaceutical […]
New future-proof EU pharmaceutical policy
Affordable medicines, preventing shortages and a climate-neutral industry – Parliament presses for a new EU pharmaceutical policy. During the plenary session in November 2021, the European Parlimanet set out a series of recommendations for the update of the EU’s pharmaceutical legislation. Faster access In 2019, the European Medicines Agency (EMA) authorised 103 orphan drugs – which are […]